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Abstract
Introduction: The impact of South Africa’s high human immunodeficiency virus (HIV) burden on cancer risk is not
fully understood, particularly in the context of antiretroviral treatment (ART) availability. We examined national
cancer trends and excess cancer risk in people living with HIV (PLHIV) compared to those who are HIV-negative.
Methods: We used probabilistic record linkage to match cancer records provided by the National Cancer Registry
to HIV data provided by the National Health Laboratory Service (NHLS). We also used text search of specific HIV
terms from the clinical section of pathology reports to determine HIV status of cancer patients. We used logistic
and Joinpoint regression models to evaluate the risk and trends in cancers in PLHIV compared to HIV-negative
patients from 2004 to 2014. In sensitivity analysis, we used inverse probability weighting (IPW) to correct for
possible selection bias.
Results: A total of 329,208 cancer cases from public sector laboratories were reported to the NCR from 2004 to
2014 with the HIV status known for 95,279 (28.9%) cancer cases. About 50% of all the female cancer cases
(n = 30,486) with a known status were HIV-positive. PLHIV were at higher risk of AIDS-defining cancers (Kaposi
sarcoma [adjusted OR:134, 95% CI:111–162], non-Hodgkin lymphoma [adjusted OR:2.73, 95% CI:2.56–2.91] and, cervix
[adjusted OR:1.70, 95% CI:1.63–1.77], conjunctival cancer [adjusted OR:21.5, 95% CI:16.3–28.4] and human papilloma
virus (HPV) related cancers (including; penis [adjusted OR:2.35, 95% CI:1.85–2.99], and vulva [adjusted OR:1.94, 95%
CI:1.67–2.25]) compared to HIV-negative patients. Analysis using the IPW population yielded comparable results.
Conclusion: There is need for improved awareness and screening of conjunctival cancer and HPV-associated
cancers at HIV care centres. Further research and discussion is warranted on inclusive HPV vaccination in PLHIV.
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Introduction
In Africa, 25.7 million people currently live with the
Human Immunodeficiency Virus (HIV) as of 2017 [1].
In South Africa, approximately 14% of the population
was living with HIV in 2017 [2]. Since the introduction
of antiretroviral treatment (ART) in 2004, there has been
an increase in longevity amongst people living with HIV
(PLHIV) in South Africa [3]. With this increase in
longevity and the known association between cancer and
HIV, the risk for cancer amongst PLHIV has increased.
However, the additional risk of cancer that PLHIV in
South Africa have compared to those who are HIV
negative in the ART era is not fully documented.
Studies in developed countries have shown a higher
burden of non-AIDS-defining cancers (NADCs) amongst
PLHIV in the ART era particularly, anal, skin, liver and
lung cancer [4, 5]. Associated with this is age, race, un-
availability of ART in some cases, HIV transmission route,
lifestyle related factors and immunosuppression [4, 6–8].
However, not all NADCs have exhibited differential rates
before and after ART. For example PLHIV have remained
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at low risk of colon, breast and prostate cancers, leading
to the possibility that not all cancers are associated with
immunosuppression [9]. In contrast, developing countries
still have a higher burden of AIDS-defining cancers
(ADCs), namely Kaposi Sarcoma (KS), cervical cancer
(CC), and non-Hodgkin lymphoma (NHL). This is largely
due to co-infections with oncogenic viruses and possibly,
poor access to HIV care including ART [10–12].
Studies on HIV and cancer done in South Africa have
involved HIV cohorts or case control studies which have
limited generalization to the general population [13, 14].
The cancer data provided by the National Cancer
Registry (NCR) lacks information on HIV status amongst
cancer patients as HIV status is not routinely collected
in the cancer registry. The South African HIV Cancer
Match (SAM) study is a probabilistic record linkage
study. It consists of a national HIV cohort created from
National Health Laboratory Service (NHLS) HIV labora-
tory data (CD4 counts, viral load, HIV tests), linked to
the NCR data, in order to study cancer risk in HIV
positive people [15]. The current study is nested within
the SAM study. We aimed to determine the impact of
HIV on cancer burden and the cancer risk in PLHIV
compared to HIV negative people or the general South
African population.
Methods
Study setting and design
The NHLS is the largest diagnostic pathology service in
South Africa. It provides laboratory and public health
services to over 80% of the South African population
[16]. This is achieved through a national network of
laboratories in all the nine provinces of South Africa.
The NHLS’ Corporate Data Warehouse (CDW) is an
electronic data repository for all public sector laboratory
data. The NCR’s main mandate is pathology-based can-
cer surveillance with both private and public laboratories
legislated to report all cancer cases to the institution.
This was a cross sectional study of all cancers diagnosed
in public sector laboratories from 2004 to 2014 with
HIV data being obtained from the NHLS’ CDW.
Study population, variables and data sources
We included all records of patients diagnosed with can-
cer in public healthcare laboratories from 2004 to 2014.
Cancer diagnosis was coded according to International
Classification of Diseases for Oncology (ICD-O-3) ex-
cluding all cancer pre-cursor lesions. Since the source of
our HIV data was the NHLS, which services the public
sector, we excluded cancer records from the private
sector. Our rationale was, if a patient accessed cancer
care at a private facility, they were more likely to access
HIV care at a private facility as well [17]. From our link-
age out of the 335,589 cancer records that were reported
from the private sector only 1122 had a known HIV
result thus supporting our hypothesis.
An individual was considered HIV positive or negative
if the HIV diagnostic test result was positive or negative
respectively. If the result was indeterminate or neither
positive nor negative, the HIV result was regarded as
unknown. In addition, HIV monitoring tests such as
HIV viral load and CD4 counts were used to assume an
HIV positive status. To supplement the NHLS HIV data-
set, repeated text mining was done to extract more HIV
results from the clinical section of pathology reports on
confirmed cases of cancer reported to the NCR. By
definition, text mining refers to the drawing out of
important and specific information from a block of text
[18]. The text mining process involved the use of key
terms used to refer or infer HIV status. The key words
used included, “HIV”, “HIV+” “HIV positive” “AIDS”,
“haart”, “ART”, “ARV”, “antiretroviral”, anti-retroviral”,
“RVD”, “RVD positive”, “retroviral disease”, “immune
suppression”, “immunosuppression”, “immuno-suppres-
sion”, “acquired immune-deficiency”, “retroreactive”,
“immunocompromised”, “HIV reactive”, “CD4”, “regi-
men 1 treatment”, “reg 1 treatment “Retroviral disease”,
“RVD”, “HIV”, “HAART” and “ARV”. From the extracted
records a series of samples were taken and reviewed to
refine the search terms. Demographic characteristics and
potential confounders such as age, gender and race were
extracted from the NCR database.
Data management
The HIV and cancer datasets were linked using the in
house CDW probabilistic record linkage algorithm. This
algorithm is used to link all the laboratory records that
belong to the same individual within the entire NHLS
database. The linkage variables include name, surname
and date of birth. For records to be considered a match,
the first letter of the first names should match and two
components of the date of birth must also match. First
names and surnames are given the same linkage weights
(40% each) and the date of birth contributes 20% of the
overall weight. For records with a recorded national
identity number, exact matching is done and this is used
to validate the probabilistic record linkage. Records that
attain a score of 90% and above are considered a match.
After linkage, duplicates were removed and private sector
cancer records were excluded and a final sample of
329,280 records remained.
Cervical cancer, KS and NHL were classified as ADCs
and the rest of the malignancies as NADCs. We also
looked at NHL subtypes namely, Burkitt lymphoma,
Diffuse large B-cell lymphoma (DLBCL), Diffuse immu-
noblastic large B-cell lymphoma (DILBCL), follicular
lymphoma Not otherwise Specified (NOS) and NHL
NOS. The NADCs were grouped into virus-related and
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virus unrelated cancers. The following were classified as
virus-related cancers according to the IARC Monograph
Working group assessment; liver cancer (hepatitis vi-
ruses), penis, vulva, vagina, anal, oropharynx, larynx and
tonsil (Human Papilloma Virus (HPV) other than cervix)
and Hodgkin’s lymphoma and nasopharyngeal cancer
(Epstein Barr Virus (EBV)) [19]. Although all the ADCs
are associated with viruses they were not included in the
virus related NADCs category. For descriptive purposes,
age was classified as 0–14, 15–19, 20–24, 25–29, 30–34,
35–39, 40–44, 45–49, 50–54, 55–59 and 60 + .
Data analysis
We determined the characteristics of cancer patients
(age, gender, race, cancer type (NADC or ADC) and
cancer diagnosis year) by HIV status (positive, negative
or unknown) with 95% confidence intervals. To deter-
mine the additional risk that PLHIV had of developing
specific cancers as per ICD-O-3 coding, logistic regres-
sion models were fitted adjusting for age (as a continu-
ous variable), gender (males and females), race (Asian,
Black, Coloured and White) and cancer diagnosis year
(modelled as a continuous variable).
We assessed trends in cancer risk for selected cancers
by plotting yearly crude odds ratios using Joinpoint re-
gression models (Joinpoint Regression Program, Version
4.6.0.0. April, 2018 Statistical Research and Applications
Branch, National Cancer Institute). The Joinpoint
program allows one to determine if the trend observed
is statistically significant or not. In most cases the inde-
pendent variable is the calendar year. Observed odds
ratios (or other parameters such as incidence rate or
counts) are joined in straight lines at each time point
hence the term joinpoint. The model goes to identify at
which time point a significant change in trend is ob-
served as well as the magnitude of the change (Annual
Percentage Change (APC)). Permutation tests are then
used to select the final model that better describes the
change in trends. To determine the contribution of HIV
to the cancer burden in South Africa, we calculated
Attributable Risk Fractions (ARFs) using adjusted odds
ratios as demonstrated by Newson [20].
Sensitivity analysis
Clinicians are more likely to request an HIV test if the
patient is symptomatic, hence creating a selection bias.
With high number of missing HIV status, inverse
probability weighting (IPW) methods were used as a
post-hoc sensitivity analysis to correct for possible selec-
tion bias. We created the weights using age, gender,
cancer diagnosis year and cancer type similar to the
method used by Dryden-Petersen et al. [10].
Analysis was done using Stata version 15 (College
Station, TX: StataCorp LP). P-values of less than 0.05
were considered to be statistically significant.
Results
From 2004 until 2014, a total of 329,208 cancers were
reported to the NCR by the public sector laboratories.
Probabilistic record linkage identified 90,796 HIV results
and through text mining of cancer pathology reports an
additional 4483 HIV results were found. Of the 95,279
(28.9%) cancer patients with a known HIV status, 46,951
(14.3%) were HIV positive. Amongst PLHIV, cancer pro-
portions were highest between the ages of 25 and 49
(Table 1 below). In contrast, 37% (n = 17,890) of all HIV
negative individuals were in the over 60 age group.
Across all the HIV status subgroups, the greater propor-
tion of cancers was observed in the Black population at
62.6% (n = 206,286). A general increase in cancer pro-
portions was observed for all cancers irrespective of the
HIV status by calendar year. Compared to the HIV nega-
tive individuals and those with an unknown status, more
ADCs were observed in PLHIV. Throughout the study
period, ADCs remained constantly higher than NADCs
in HIV positive individuals, (Fig. 1 below).
Correcting for age, gender, race, and year of cancer
diagnosis, cancer risk was highest in the HIV positive
population for all ADCs (Kaposi sarcoma, NHL, and
cervical cancer) with an overall adjusted odds ratio of
4.5 (95% CI =4.35–4.65). The NHL subtypes Burkitt’s
lymphoma (adjusted OR: 6.48, 95% CI (5.21–8.07)),
Diffuse large B-cell lymphoma (DLBCL) (adjusted OR
2.93 95% CI (2.67–3.22)) and Diffuse immunoblastic
large B-cell lymphoma (DILBCL) (adjusted OR 12.1 95%
CI (9.02–16.3)). Compared to HIV negative individuals,
PLHIV were 0.74 times less likely to develop NADCs
(adjusted OR: 0.26, 95% CI (0·25–0.26). As a group,
virus-related NADCs were not significantly associated
with HIV but most of the HPV-associated cancers such
as anal, penile, vulva and lip and Hodgkin’s lymphoma
(EBV-associated), were high risk in HIV positive individ-
uals [p < 0.0001]. Liver cancer, which is associated with
hepatitis viruses, was not significantly associated with
HIV. People living with HIV were at a higher risk for
Squamous Cell Carcinoma (SCC) of the skin, Basal
Cell Carcinoma (BCC), eye, and conjunctival cancers
(p < 0.0001). Non-virus related NADCs were also not
associated with HIV. The weighted analysis produced
results that were comparable to the complete case
analysis (Table 2).
Trends in cancer risk for selected individual cancers
varied, with significant increases observed for cervix,
anus, vulva, conjunctiva and penis from 2004 to 2014 in
PLHIV (Fig. 2 below). Although the APC was not signifi-
cant for Kaposi sarcoma, there was a substantial
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Table 1 Characteristics and distribution of public sector cancer cases by HIV status, 2004–2014
HIV POSITIVE HIV NEGATIVE HIV UNKNOWN
Characteristic n = 46,951 Proportion (95% CI) n = 48,328 Proportion (95% CI) n = 234,001 Proportion (95% CI)
Gender
Female 30,487 0.65(0.645–0.654) 30,032 0.62(0.617–0.626) 129,051 0.55(0.549–0.554)
Male 16,443 0.35(0.346–0.355) 18,287 0.38(0.374–0.383) 104,413 0.45(0.444–0.448)
Missing 21 0(0–0.001) 9 0(0–0) 538 0(0.002–0.002)
Age
0–14 590 0.01(0.012–0.014) 2755 0.06(0.055–0.059) 3091 0.01(0.013–0.014)
15–19 338 0.01(0.006–0.008) 582 0.01(0.011–0.013) 1331 0.01(0.005–0.006)
20–24 1317 0.03(0.027–0.03) 742 0.02(0.014–0.016) 2407 0.01(0.01–0.011)
25–29 3915 0.08(0.081–0.086) 1020 0.02(0.02–0.022) 4839 0.02(0.02–0.021)
30–34 6733 0.14(0.14–0.147) 1295 0.03(0.025–0.028) 7822 0.03(0.033–0.034)
35–39 7773 0.17(0.162–0.169) 2250 0.05(0.045–0.048) 10,468 0.04(0.044–0.046)
40–44 7220 0.15(0.151–0.157) 3452 0.07(0.069–0.074) 14,051 0.06(0.059–0.061)
45–49 5812 0.12(0.121–0.127) 5081 0.11(0.102–0.108) 17,996 0.08(0.076–0.078)
50–54 4671 0.1(0.097–0.102) 6291 0.13(0.127–0.133) 22,903 0.1(0.097–0.099)
55–59 3351 0.07(0.069–0.074) 6588 0.14(0.133–0.139) 26,590 0.11(0.112–0.115)
60+ 4738 0.1(0.098–0.104) 17,890 0.37(0.366–0.374) 113,501 0.49(0.483–0.487)
Missing 493 0.01(0.01–0.011) 382 0.01(0.007–0.009) 9003 0.04(0.038–0.039)
Race
Asian 333 0.01(0.006–0.008) 826 0.02(0.016–0.018) 6869 0.03(0.029–0.03)
Black 40,004 0.85(0.849–0.855) 25,335 0.52(0.52–0.529) 140,946 0.6(0.6–0.604)
Coloured 2620 0.06(0.054–0.058) 10,107 0.21(0.206–0.213) 28,793 0.12(0.122–0.124)
White 1548 0.05(0.05–0.054) 1641 0.22(0.212–0.219) 10,115 0.2(0.2–0.204)
Missing 2446 0.03(0.031–0.035) 10,419 0.03(0.032–0.036) 47,279 0.04(0.042–0.044)
Province
Eastern Cape 3314 0.07(0.068–0.073) 4020 0.08(0.081–0.086) 32,379 0.14(0.137–0.14)
Free State 4364 0.09(0.09–0.096) 5178 0.11(0.104–0.11) 16,773 0.07(0.071–0.073)
Gauteng 20,957 0.45(0.442–0.451) 15,534 0.32(0.317–0.326) 62,004 0.26(0.263–0.267)
Kwazulu-Natal 1434 0.03(0.029–0.032) 712 0.01(0.014–0.016) 35,268 0.15(0.149–0.152)
Limpopo 3661 0.08(0.076–0.08) 553 0.01(0.01–0.012) 15,529 0.07(0.065–0.067)
Mpumalanga 3277 0.07(0.067–0.072) 593 0.01(0.011–0.013) 9390 0.04(0.039–0.041)
North West 2869 0.06(0.059–0.063) 1526 0.03(0.03–0.033) 9700 0.04(0.041–0.042)
Northern Cape 1098 0.02(0.022–0.025) 1396 0.03(0.027–0.03) 6561 0.03(0.027–0.029)
Western Cape 5962 0.13(0.124–0.13) 18,791 0.39(0.384–0.393) 45,466 0.19(0.193–0.196)
Missing 15 0(0–0) 25 0(0–0.001) 932 0(0.004–0.004)
Type of cancer
NADC 17,604 0.37(0.371–0.379) 34,965 0.72(0.72–0.727) 172,260 0.74(0.734–0.738)
ADC 27,125 0.58(0.573–0.582) 10,288 0.21(0.209–0.217) 42,992 0.18(0.182–0.185)
Primary site unknown 2222 0.05(0.045–0.049) 3075 0.06(0.061–0.066) 18,750 0.08(0.079–0.081)
Cancer diagnosis year
2004 1026 0.02(0.021–0.023) 1767 0.04(0.035–0.038) 23,656 0.1(0.1–0.102)
2005 2337 0.05(0.048–0.052) 3281 0.07(0.066–0.07) 21,784 0.09(0.092–0.094)
2006 3038 0.06(0.062–0.067) 3678 0.08(0.074–0.078) 23,101 0.1(0.098–0.1)
2007 3616 0.08(0.075–0.079) 3882 0.08(0.078–0.083) 22,376 0.1(0.094–0.097)
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decrease in risk between 2004 and 2006 with no changes
observed thereafter. Prior to 2011, there was no signifi-
cant difference in risk for anal, vulva and penile cancers
between those who were HIV negative and PLHIV but
significant increases were observed after 2011. For Bur-
kitt’s lymphoma and NHL, whilst the risk was higher in
PLHIV, there was relatively no change over the study
period. Although insignificant, the trend line for
Hodgkin’s lymphoma was suggestive of an increase in
cancer risk.
There was no shift in burden between ADCs and
NADCs observed amongst incident cancers in PLHIV
(Fig. 1). Using weighted estimates of the odds ratio, 41%
of all ADCs reported between 2004 and 2014 were
attributable to HIV. The contribution of HIV on ADCs
increased by 22% within the study period (Fig. 3). No
particular contribution by HIV towards NADCs as a
whole was noted, given the negative ARFs. The same
was true for the category virus-related NADCs (Fig. 3),
HIV did not seem to contribute to the burden of virus
related NADCs amongst PLHIV in the public sector.
However, the “protective” effect of HIV has been waning
overtime.
Discussion
Over the period 2004–2014 (ART era), the risk of all
ADCs and some virus-related NADCs was higher
amongst HIV positive individuals compared to those
who were HIV negative. The strongest association was
observed between KS [adjusted OR: 134, 95% CI 111–
161], conjunctival cancer [adjusted OR: 21.5, 95% CI
16.3–28.4] as well as Burkitt’s lymphoma [adjusted OR:
6.48, 95% CI 5.21–8.07]. Amongst the virus-related
NADCs, HPV-associated cancers such as lip, anal, penile
and vulva cancer had the strongest associations with
HIV. Compared to those who were HIV negative,
squamous cell carcinoma of the skin (SCC), basal cell
carcinoma (BCC) and conjunctival cancer were the only
virus-unrelated NADCs that were significantly associ-
ated with HIV. Over time, amongst PLHIV a significant
Table 1 Characteristics and distribution of public sector cancer cases by HIV status, 2004–2014 (Continued)
HIV POSITIVE HIV NEGATIVE HIV UNKNOWN
Characteristic n = 46,951 Proportion (95% CI) n = 48,328 Proportion (95% CI) n = 234,001 Proportion (95% CI)
2008 4434 0.09(0.092–0.097) 4378 0.09(0.088–0.093) 22,506 0.1(0.095–0.097)
2009 4782 0.1(0.099–0.105) 4839 0.1(0.097–0.103) 21,917 0.09(0.092–0.095)
2010 5194 0.11(0.108–0.113) 4926 0.1(0.099–0.105) 21,279 0.09(0.09–0.092)
2011 5714 0.12(0.119–0.125) 5485 0.11(0.111–0.116) 19,769 0.08(0.083–0.086)
2012 5931 0.13(0.123–0.129) 5749 0.12(0.116–0.122) 21,592 0.09(0.091–0.093)
2013 5719 0.12(0.119–0.125) 5401 0.11(0.109–0.115) 18,881 0.08(0.08–0.082)
2014 5159 0.11(0.107–0.113) 4942 0.1(0.1–0.105) 17,141 0.07(0.072–0.074)
Fig. 1 Percentage contribution of ADCs and NADCs to the total cancer burden amongst PLHIV in South Africa, 2004–2014. A comparison of
incident cancers by cancer type in PLHIV. Given in the graph is a percentage of the total cancers in PLHIV each year
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Table 2 Odds ratios for cancer in PLHIV by complete case analysis and by weighted analysis
Cancer Complete case Weighted
Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p-value
ADC 4.50 (4.35–4.65) < 0.0001 3.46 (3.33–3.59) < 0.0001
Kaposi 134 (111–161) < 0.0001 98.8 (80.9–120) < 0.0001
Cervix 1.70 (1.63–1.77) < 0.0001 1.68 (1.60–1.76) < 0.0001
NHL 2.73 (2.56–2.91) < 0.0001 2.89 (2.71–3.08) < 0.0001
Burkitt’s lymphoma 6.48 (5.21–8.07) < 0.0001 7.83 (6.38–9.62) < 0.0001
Non-Hodgkins NOS 4.26 (3.4–5.34) < 0.0001 4.85 (3.88–6.07) < 0.0001
DLBCL 2.93 (2.67–3.22) < 0.0001 3.27 (3.00–3.59) < 0.0001
DILBCL 12.1 (9.02–16.3) < 0.0001 12.0 (8.91–16.1) < 0.0001
Follicular 0.65 (0.49–0.87) 0.004 0.73 (0.55–0.98) 0.038
NADC 0.26 (0.25–0.26) < 0.0001 0.36 (0.35–0.38) < 0.0001
Virus-related NADC 0.75 (0.71–0.78) < 0.0001 0.77 (0.73–0.82) < 0.0001
Anus 1.63 (1.33–2.00) < 0.0001 1.61 (1.30–1.99) < 0.0001
Hodgkin’s lymphoma 1.22 (1.09–1.37) < 0.0001 1.43 (1.27–1.61) < 0.0001
Liver 0.45 (0.39–0.53) < 0.0001 0.51 (0.42–0.61) < 0.0001
Vulva 1.94 (1.67–2.25) < 0.0001 1.82 (1.58–2.10) < 0.0001
Vagina 0.83 (0.67–1.03) 0.09 0.88 (0.70–1.11) 0.29
Penis 2.35 (1.85–2.99) < 0.0001 2.06 (1.63–2.61) < 0.0001
Lip, oral cavity and Pharynx (C00-C14) 0.55 (0.50–0.59) < 0.0001 0.67 (0.61–0.73) < 0.0001
Gum 0.74 (0.41–1.36) 0.34 0.90 (0.46–1.76) 0.76
Lip 2.72 (1.71–4.32) < 0.0001 3.47 (1.95–6.16) < 0.0001
Mouth 0.56 (0.49–0.66) < 0.0001 0.63 (0.53–0.75) < 0.0001
Naso-oropharynx 0.48 (0.42–0.56) < 0.0001 0.57 (0.48–0.68) < 0.0001
Salivary gland 0.65 (0.51–0.82) < 0.0001 0.71 (0.54–0.93) 0.01
Tongue 0.51 (0.43–0.60) < 0.0001 0.57 (0.47–0.70) < 0.0001
Virus-unrelated NADC 0.30 (0.29–0.31) < 0.0001 0.43 (0.42–0.45) < 0.0001
BCC 1.27 (1.08–1.49) < 0.0001 1.39 (1.17–1.67) < 0.0001
Bladder 0.74 (0.61–0.89) < 0.0001 0.86 (0.69–1.08) 0.2
Bone 0.32 (0.26–0.40) < 0.0001 0.41 (0.30–0.54) < 0.0001
Brain 0.27 (0.22–0.34) < 0.0001 0.34 (0.26–0.43) < 0.0001
Colorectal 0.43 (0.38–0.47) < 0.0001 0.55 (0.48–0.62) < 0.0001
Eye 5.9 (5.11–6.82) < 0.0001 7.73 (6.60–9.05) < 0.0001
Conjunctiva 21.5 (16.3–28.4) < 0.0001 20.8 (15.2–28.5) < 0.0001
Haematology 0.49 (0.37–0.65) < 0.0001 0.58 (0.43–0.80) < 0.0001
Kidney 0.18 (0.15–0.21) < 0.0001 0.23 (0.19–0.29) < 0.0001
Larynx 0.56 (0.49–0.64) < 0.0001 0.62 (0.53–0.72) < 0.0001
Leukaemia 0.25 (0.23–0.28) < 0.0001 0.33 (0.30–0.37) < 0.0001
Lung 0.52 (0.48–0.57) < 0.0001 0.62 (0.56–0.68) < 0.0001
Melanoma 0.77 (0.63–0.93) 0.01 0.95 (0.76–1.20) 0.69
Mesothelioma 0.50 (0.34–0.75) < 0.0001 0.51 (0.32–0.80) < 0.0001
Myeloma 0.61 (0.52–0.71) < 0.0001 0.75 (0.63–0.89) < 0.0001
Oesophagus 0.57 (0.52–0.64) < 0.0001 0.58 (0.52–0.66) < 0.0001
Pancreas 0.43 (0.33–0.58) < 0.0001 0.60 (0.42–0.84) < 0.0001
SCC Skin 1.83 (1.64–2.04) < 0.0001 1.88 (1.67–2.11) < 0.0001
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upward trend in risk was observed for cancer of the
conjunctiva and anogenital cancers, including cervix.
The spectrum of cancers observed in this study was
comparable to what has been observed in other African
countries. Similar to a case control study by Stein et al.
conducted before ART was available, the risk of KS,
cervical cancer, NHL, anogenital cancers other than
cervix and SCC skin was elevated amongst PLHIV in
our present study [21]. For KS, the risk was higher com-
pared to the one reported by Stein et.al (adjusted OR:
50.4, 95% CI 34.2–74.3) [21]. In both our study and the
Stein pre-ART study, the odds ratios were adjusted for
age, gender, race and year of diagnosis, which allowed
for comparability. Possible explanations for the higher
risk in our study is that, until 2016 when the universal
test and treat policy was adopted in South Africa, treat-
ment initiation was dependent on CD4 count [22]. In
2004, ART became freely available in the public sector
with patients who had CD4 counts of less than 200 cell/
μl or in the WHO stage IV of disease being eligible for
treatment [23]. Patients were also evaluated to deter-
mine if they were psychological fit to receive the treat-
ment. In 2010 in addition to the 2004 recommendations,
those who had a co-infection with TB were also auto-
matically eligible for the free ART [24]. In 2011, the cri-
teria were then expanded to include all patients who had
a CD4 count of less than 350 cells/μl [24]. These CD4
count thresholds led to a high proportion of immuno-
suppressed individuals with a high burden of disease, a
risk factor for ADCs [14, 22]. As a result, the risk of KS
remained elevated even after ART introduction. More-
over, it is possible that the pick-up rate of KS at HIV
clinics improved with the expansion of ART and
improvements in HIV treatment policies in South Africa
hence the greater strength of association observed.
Despite the high risk reported for KS in our study, it was
lower than reported in other studies particularly those
done in the developed countries [4, 25]. In South Africa,
the prevalence of Human Herpes Virus (HHV8) was
high even before the HIV era, therefore creating a high
KS background risk [26]. In addition to this, clinical
diagnosis of KS is quite prevalent in the African context
with no biopsies or other samples being sent to the
laboratory [27]. Therefore, under-reporting of KS to the
pathology-based cancer registry may have been possible.
In contrast, the risk reported in our study for NHL
(adjusted OR: 2.73, 95% CI 2.56–2.91) was lower than
the one reported by Stein et.al. (adjusted OR: 6.1, 95%
CI 4.4–8.4) which points to a possible reduction in risk
of NHL after the introduction of ART [21]. There was
no change noted before and after ART in overall cervical
cancer risk although an upward trend was observed in
the ART era. This is in line with other reports from
Africa with various reasons being put forth to account
for the increase in cervical cancer risk even with the
introduction of ART. These include advanced disease
upon ART initiation and older age [28, 29]. Another
theory that has been put forward is the lack of a rela-
tionship between cervical cancer risk and immunosup-
pression. Some studies have demonstrated that low CD4
counts do not necessarily amount to increased risk of
cervical cancer and other HPV-related cancers [29]. As
such, restoration of immunity with ART will not neces-
sarily lead to a reduced risk of cervical cancer. In
addition, the prevalence of HPV (a known risk factor for
cervical cancer) is higher amongst women living with
HIV [29, 30]. Possible co-infection with HPV has also
been highlighted in this study with increased risk
Table 2 Odds ratios for cancer in PLHIV by complete case analysis and by weighted analysis (Continued)
Cancer Complete case Weighted
Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p-value
Skin 0.95 (0.77–1.16) 0.6 1.11 (0.87–1.41) 0.41
Small intestines 0.33 (0.23–0.48) < 0.0001 0.35 (0.24–0.53) < 0.0001
Stomach 0.43 (0.37–0.49) < 0.0001 0.58 (0.49–0.70) < 0.0001
Thyroid 0.75 (0.59–0.95) 0.02 1.01 (0.74–1.37) 0.97
Uterus 0.38 (0.34–0.43) < 0.0001 0.44 (0.39–0.50) < 0.0001
Breast 0.43 (0.41–0.45) < 0.0001 0.50 (0.47–0.53) < 0.0001
Placenta 0.85 (0.58–1.24) 0.39 1.05 (0.70–1.56) 0.83
Prostate 0.85 (0.76–0.95) < 0.0001 0.95 (0.84–1.08) 0.46
Testis 0.37 (0.26–0.53) < 0.0001 0.48 (0.32–0.74) < 0.0001
Poorly specified histology at any site 0.82 (0.77–0.88) < 0.0001 0.95 (0.88–1.03) 0.2
OR Odds ratios determined using logistic regression models adjusting for age, gender, race, province and year of cancer diagnosis, NHL non-Hodgkin’s lymphoma,
DLBCL Diffuse large B-cell lymphoma, DILBCL Diffuse Immunoblastic Large B-cell lymphoma, NOS Not Otherwise Specified, BCC Basal cell carcinoma, ADC AIDS
defining cancer, NADC non-AIDS defining cancer, SCC skin squamous cell carcinoma of the skin, Virus-related NADCs liver cancer (hepatitis viruses), penis, vulva,
vagina, anal, lip, mouth, gum, salivary gland and tonsil (Human Papilloma Virus (HPV) associated malignancies other than cervix), and Hodgkin’s lymphoma and
nasopharyngeal cancer (Epstein Barr Virus (EBV)). The weighted analysis included inverse probability weights estimated from known HIV status age, gender, cancer
diagnosis and cancer diagnosis year
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amongst PLHIV observed for HPV associated cancers
such as vulva, anus, penis and lip.
Besides the ADCs and HPV related cancers, we ob-
served other additional cancers were strongly associated
with HIV in the ART era. Compared to HIV negative
individuals, the risk of conjunctival cancer, Hodgkin’s
lymphoma and BCC was also higher in PLHIV in our
study. Before ART, there were no reports of conjunctival
cancer and BCC as being high risk amongst PLHIV in
South Africa [21]. The association between conjunctival
cancer and HIV has been reported in Africa [29, 31].
High rates of solar radiation and unproved associations
with HPV have been cited as possible reasons why this
cancer is common in Sub-Saharan Africa compared to
other parts of the world [29]. Like SCC skin, we
observed stronger associations between HIV and BCC.
Reports have linked age and white race to higher BCC
risk in PLHIV with immunosuppression and increased
viral loads only being linked to SCC skin [32, 33]. On
the other hand PLHIV were less likely to develop
virus-unrelated cancers such as breast and prostate
which is in line with the literature [4, 7, 25]. Lower risks
were also observed for lung and liver cancers in PLHIV
consistent with the results reported by Stein et al. but
contrary to other reports especially those done in re-
source rich areas [4, 7, 9]. In the resource rich countries,
there is a higher prevalence of lifestyle related factors
such as smoking which results in lung cancer and in-
creased alcohol intake which results in liver cancer in
HIV cohorts [7]. In our study, it is still uncertain why
the liver and lung cancer risk was lower in PLHIV
compared to HIV negative individuals.
In the ART era, different cancer trends have been ob-
served, with ADCs decreasing upon ART introduction
Fig. 2 Trends in cancer risk for selected cancers amongst PLHIV in the South African public health sector, 2004–2014. The line graphs were fitted
in Joinpoint using crude odds ratios (dots). The annual percentage change in odds ratios was significant (p-value < 0.05) for all cancers selected
for in-depth analysis of trends except for Kaposi sarcoma, Burkitt’s lymphoma, NHL and Hodgkin’s lymphoma
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in other settings [6, 9, 25]. In particular, KS has declined
with the introduction and expansion of ART hence
supporting the association between this cancer and
immunosuppression [6, 25, 34]. In our study following
the initial drop in KS risk after ART introduction in
2004, there has not been a significant change in risk
amongst PLHIV in the ART era [10]. This is similar to
what was reported in a recent study done in Botswana
which demonstrated a decrease in KS risk with ART
introduction but no significant change with increased
roll out of ART [10]. The arguments for this are similar
to the reasons why KS risk was reported as higher in our
Fig. 3 Trend in Attributable risk fractions amongst PLHIV in the South African public health sector, 2004-2014. Using adjusted odds ratios
adjusting for age, gender, race, year of cancer diagnosis, and Province. ARF = Attributable Risk Fraction. ADC = AIDS defining cancer (includes
Kaposi sarcoma, non-Hodgkin’s lymphoma and cervical cancer). NADCs = Non-AIDS Defining Cancers. Virus-related NADCs = liver cancer (hepatitis
viruses), penis, vulva, vagina, anal, lip, mouth, gum, salivary gland and tonsil (Human Papilloma Virus (HPV) associated malignancies other than
cervix), and Hodgkin’s lymphoma and nasopharyngeal cancer (Epstein Barr Virus (EBV)
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study compared to the pre-ART era, which include HIV
treatment policies and improved pick-up rate. The trend
in NHL risk exhibited a slight but insignificant decrease
over the 11-year period. Whilst some studies have
shown decreasing trend in NHL in the ART era in
PLHIV others have shown stable trends even with the
increased rollout of ART [10, 25]. This has largely been
because of Burkitt’s lymphoma as its incidence has
remained constant even in the ART era.
Also showing increasing trends in the ART era were
most HPV related anogenital cancers (cervix, anus, penis
and vulva). Although anal cancer is on the rise, the risk
reported is not as high as observed in developed
countries. This is possibly due to the difference in HIV
epidemiology between South Africa and developed
countries. In the latter, the main mode of HIV transmis-
sion is men who have sex with men (MSM) through
receptive anal sex where as in South Africa, HIV trans-
mission is mainly heterosexual [4, 5]. Co-infection with
HPV is higher amongst people living with HIV with the
routes of transmission being similar to HIV [35]. Both
anal and cervical cancer are associated with HPV, but
the different transmission routes will result in more
cervical cancer in the African context and more anal
cancer in developed countries.
This was the first nationwide study to compare cancer
risk amongst the HIV positive and HIV negative people
in the ART era. Laboratory confirmation of both cancer
and HIV allowed for high specificity of HIV and cancer
diagnosis. Although a greater proportion of the HIV
status was unknown, the methods used to ascertain HIV
status such as probabilistic record linkage and text
search ensured that we extracted and matched most of
the available HIV records. In addition, probabilistic
record linkage allowed us to identify records belonging
to the same individual even in the absence of a unique
identifier. The greater percentage of black population
with HIV and cancer was reflective of the HIV epidemic
in South Africa as well as patterns of access to public
health services. In addition to this, the use of IPW
allowed for assessment of the risk estimates given the
possible selection bias due to the high proportion of
missing HIV status. The conclusions from the weighted
analysis (IPW) were comparable with the complete case
analysis. Moreover, women were well represented with
enough numbers for cancers that are common in
females to be fully analysed.
Despite all these strengths, our study had limitations.
Due to its laboratory-based surveillance system, the
NCR underreports some cancers that are diagnosed
clinically or radiologically like lung and liver cancers.
This might potentially result in misrepresentation of as-
sociation between HIV and these cancers. Although
probabilistic record linkage allowed for matching, in the
absence of a unique identifier there is still room for
some false matches. The national unique identifier re-
mains the gold standard. Another limitation of our study
was overrepresentation of the HIV positive individuals.
Doctors are more likely to note down the HIV status of
a patient if the patient is tested positive. In addition to
this, specific cancers such as KS and other symptoms
that are known to be associated with HIV are more
likely to prompt a clinician to request an HIV test to be
done on the patient [36]. This will result in a higher
HIV testing and subsequently higher HIV prevalence
compared to the general population. Therefore, with the
text mining of doctors’ clinical notes in pathology-re-
ports, we were more likely to pick up those that were
tested positive than those that were tested negative or
never tested. As such, our study also shares the same
limitations as proportionate incidence ratio studies. The
increased risk observed may be a reflection of a higher
HIV prevalence resulting in more cancer cases that are
associated with HIV in our study population compared
to that in the general population. The evaluation of
cancer risk in PLHIV as a function of time was not
possible in this study. However, through the SAM study
determination of cancer risk with a person-time denom-
inator will be possible. Data on other potential con-
founders such as lifestyle patterns (smoking, alcohol
intake, diet and exercise) and other opportunistic infec-
tions was also not available. Access to this information
would have possibly made the results more robust.
Conclusion
PLHIV have a higher risk for all ADCs and most
virus-related NADCs. The risk of anogenital cancers and
conjunctival cancer continues to rise in the ART era and
suggests that, ART alone is inadequate in reducing can-
cer in PLHIV. Most of these cancers are HPV-related.
Targeted public health interventions for HPV such as
screening and expansion of HPV vaccination (for
cervical cancer) amongst PLHIV are essential in redu-
cing the burden. To consolidate these efforts, ART
expansion and availability as well as retention in care
should be strengthened. With the introduction of
universal ART treatment in 2016, further decreases in
ADCs are expected provided individuals report to health
care centres before the HIV disease has advanced.
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